We have a diversified and balanced clinical development pipeline that covers multiple therapeutic areas, including CNS, cardiovascular and immunological disorders, as well as orphan diseases.

         

Compound

Mechanism of action

Target indication

Status

More Information

Daridorexant

Dual orexin receptor antagonist

Insomnia

Commercially available as QUVIVIQ™ in the US,
and the first countries in Europe

Under review in Switzerland and Canada

Phase 3 in Japan successful – filing expected in H1 2023

Phase 2 in pediatric insomnia – recruiting

Investor webcast

Aprocitentan*

Dual endothelin receptor antagonist

Resistant hypertension management

Phase 3 successful – filing by end 2022

Investor webcast

Clazosentan

Endothelin receptor antagonist

Cerebral vasospasm assoc.
with aneurysmal subarachnoid hemorrhage

Commercially available as PIVLAZ™ in Japan

Global Phase 3 – recruitment complete

Investor webcast

Lucerastat

Glucosylceramide synthase inhibitor

Fabry disease

Phase 3 primary endpoint not met, Open Label Extension study (OLE) ongoing

  

Selatogrel

P2Y12 receptor antagonist

Suspected acute myocardial infarction

Phase 3 recruiting

Investor webcast

Cenerimod

S1P1 receptor modulator

Systemic lupus erythematosus

Phase 3 in preparation

  

ACT-539313

Selective orexin 1 receptor antagonist

Under evaluation

-

  

ACT-1004-1239

ACKR3 / CXCR7 antagonist

Multiple sclerosis

Phase 2 in preparation

  

Sinbaglustat

GBA2/GCS inhibitor

Rare lysosomal storage disorders

Phase 1 complete

  

ACT-1014-6470

-

Immunology

Phase 1

  

ACT-777991

CXCR3 antagonist

Recent-onset Type 1 diabetes

Phase 1

  


* In collaboration with Janssen Biotech to jointly develop aprocitentan, Janssen Biotech has sole commercialization rights worldwide

Neurocrine Biosciences has a global license to develop and commercialize ACT-709478 (NBI-827104), Idorsia's novel T-type calcium channel blocker. ACT-709478 is currently being investigated in a Phase 2 study for the treatment of a rare form of pediatric epilepsy.

 

Innovation fact sheet

For investors, we provide more information on how Idorsia is innovating to change treatment paradigms in our innovation fact sheet. Please visit the investor section for more information.

"I enjoy working for Idorsia because it has the culture of "let's do it" instead of "it's impossible"."

Application Manager, Corporate IT